Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vertex To Sell Rights Of European Milestone Payments For Telaprevir
Vertex Pharmaceuticals is expected to sell the rights to certain milestone payments tied to the future regulatory filing, approval and market launch of its hepatitis C virus (HCV)
Vertex Pharmaceuticals is expected to sell the rights to certain milestone payments tied to the future regulatory filing, approval and market launch of its hepatitis C virus (HCV)
Forest Laboratories and its wholly-owned subsidiary, Forest Laboratories Holdings and Lundbeck have entered into a settlement agreement with Sun Pharma and Caraco, regarding pending patent infringement disputes. Its
Bayer Vital is going to launch the OTC Proton Pump Inhibitor (PPI), omeprazole in Germany under the Antra brand, beginning in August. With Antra, patients would have a
Astellas Pharma’ FAMOUS trial, in which Gaster (famotidine) was effective on the prevention of peptic ulcers in uses of low-dose aspirin, was observed and reported in the medical
Glenmark Generics is all set to launch Fosinopril Sodium and Hydrochlorothiazide tablets in the US market. Fosinopril Sodium and Hydrochlorothiazide (HCTZ) tablets are available in both 10mg/12.5mg and
The supervisory board of Celesio has approved the majority holding of 50.1% in pharmaceutical wholesaler Panpharma. The company said that it has spent about two years thoroughly analysing
Dharma Therapeutics’ active transdermal delivery technology, which administers lidocaine and epinephrine through the skin via a mild electric current, has demonstrated safety and efficacy in a phase 2
Johnson & Johnson has completed its acquisition of Cougar. Johnson & Johnson’s tender offer for shares of Cougar common stock expired on July, 9, 2009, with approximately 20,148,930
Daiichi Sankyo and Eli Lilly have received approval for Effient (prasugrel) tablets from the FDA, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with
HST Global has announced the termination of its Letter of Intent Agreement to purchase Bryomed International. HST Global looks forward to maintaining the relationship between the parties and